专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明申请

WO2003080100A2 DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HOMO SAPIENS G - PROTEIN - COUPLED RECEPTOR 63 (GPR63) 审中-公开
标题翻译：与HOMO SAPIENS相关的疾病的诊断和治疗G-蛋白质 - 偶联受体63（GPR63）
公开(公告)号：WO2003080100A2
公开(公告)日：2003-10-02
申请号：PCT/EP2003/002686
申请日：2003-03-14
申请人： BAYER AKTIENGESELLSCHAFT , GOLZ, Stefan , BRÜGGEMEIER, Ulf , GEERTS, Andreas
发明人： GOLZ, Stefan , BRÜGGEMEIER, Ulf , GEERTS, Andreas
IPC分类号： A61K38/00
CPC分类号： C12Q1/6883 , C12Q2600/136 , C12Q2600/158 , G01N33/566 , G01N33/74 , G01N2333/726 , G01N2500/00
摘要： The invention provides a human GPR63 receptor which is associated with hematological diseases, disorders of the peripheral and central nervous system, COPD, asthma, genito-urological disorders, gastro-intestinal diseases, inflammation diseases and cancer. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological diseases, disorders of the peripheral and central nervous system, COPD, asthma, genito-urological disorders, gastro-intestinal diseases, inflammation diseases and cancer. The invention also features compounds which bind to and/or activate or inhibit the activity of GPR63 as well as pharmaceutical compositions comprising such compounds.
摘要翻译：本发明提供了与血液疾病，外周和中枢神经系统疾病，COPD，哮喘，泌尿系统疾病，胃肠疾病，炎症疾病和癌症有关的人类GPR63受体。本发明还提供了用于鉴定可用于治疗或预防血液疾病，外周和中枢神经系统疾病，COPD，哮喘，泌尿系统疾病，胃肠疾病，炎症疾病和癌症的化合物的测定。本发明还涉及结合和/或活化或抑制GPR63活性的化合物以及包含这些化合物的药物组合物。

82. 发明申请

WO2003080097A2 DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HOMO SAPIENS G - PROTEIN - COUPLED RECEPTOR 7 (GPR7) 审中-公开
标题翻译：与HOMO SAPIENS相关的疾病诊断和治疗G - 蛋白 - 偶联受体7（GPR7）
公开(公告)号：WO2003080097A2
公开(公告)日：2003-10-02
申请号：PCT/EP2003/002404
申请日：2003-03-10
申请人： BAYER AKTIENGESELLSCHAFT , GOLZ, Stefan , BRÜGGEMEIER, Ulf , GEERTS, Andreas
发明人： GOLZ, Stefan , BRÜGGEMEIER, Ulf , GEERTS, Andreas
IPC分类号： A61K38/00
CPC分类号： C12Q1/6883 , C12Q2600/136 , C12Q2600/158 , G01N33/566 , G01N33/74 , G01N2333/726 , G01N2500/00
摘要： The invention provides a human GPR7 which is associated with the cardiovascular, hematological, peripheral and central nervous system diseases, COPD, asthma, inflammation, gastro-intestinal diseases and cancer. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular, hematological, peripheral and central nervous system diseases, COPD, asthma, inflammation, gastro-intestinal diseases and cancer. The invention also features compounds which bind to and/or activate or inhibit the activity of GPR7 as well as pharmaceutical compositions comprising such compounds.
摘要翻译：本发明提供了与心血管，血液学，外周和中枢神经系统疾病，COPD，哮喘，炎症，胃肠道疾病和癌症相关的人类GPR7。本发明还提供了用于鉴定可用于治疗或预防心血管，血液，外周和中枢神经系统疾病，COPD，哮喘，炎症，胃肠道疾病和癌症的化合物的测定。本发明还涉及结合和/或活化或抑制GPR7活性的化合物以及包含这些化合物的药物组合物。

83. 发明申请

WO2003072122A3 DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH ENDOTHELIAL DIFFERENTIATION LYSOPHOSPHATIC ACID G-PROTEIN-COUPLED RECEPTOR 7 (EDG7) 审中-公开
公开(公告)号：WO2003072122A3
公开(公告)日：2003-09-04
申请号：PCT/EP2003/001403
申请日：2003-02-13
申请人： BAYER HEALTHCARE AG , GOLZ, Stefan , BRÜGGEMEIER, Ulf , GEERTS, Andreas
发明人： GOLZ, Stefan , BRÜGGEMEIER, Ulf , GEERTS, Andreas
IPC分类号： A61K38/00
摘要： The invention provides a human EDG7 which is associated with the cardiovascular, haemaotological, peripheral and central nervous system diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular, haemaotological, peripheral and central nervous system diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of EDG7 as well as pharmaceutical compositions comprising such compounds.

84. 发明申请

WO2003065045A3 DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH THE GPR65 RECEPTOR 审中-公开
公开(公告)号：WO2003065045A3
公开(公告)日：2003-08-07
申请号：PCT/EP2003/000477
申请日：2003-01-20
申请人： BAYER HEALTHCARE AG , GOLZ, Stefan , BRÜGGEMEIER, Ulf , GEERTS, Andreas
发明人： GOLZ, Stefan , BRÜGGEMEIER, Ulf , GEERTS, Andreas
IPC分类号： G01N33/74
摘要： The present invention is directed to a polynucleotide sequence of a novel G-Protein Coupled Receptor GPR65 receptor. The invention also provides the human GPR65 receptor associated with the hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, genito-urinary diseases, inflammation diseases and cancer. The invention also provides assays for the identification of compounds useful for the modulation of hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, genito-urinary diseases, inflammation diseases and cancer for treating or preventing hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, genito-urinary diseases, inflammation diseases and cancer associated with expression of the GPR65 receptor.

85. 发明申请

WO2003065044A3 DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH GPR72 审中-公开
公开(公告)号：WO2003065044A3
公开(公告)日：2003-08-07
申请号：PCT/EP2003/000476
申请日：2003-01-20
申请人： BAYER HEALTHCARE AG , GOLZ, Stefan , BRÜGGEMEIER, Ulf , GEERTS, Andreas
发明人： GOLZ, Stefan , BRÜGGEMEIER, Ulf , GEERTS, Andreas
IPC分类号： G01N33/74
摘要： Diagnostics and therapeutics for diseases associated with GPR72Abstract of DisclosureThe invention also provides a human GPR72 which is associated with the hematological diseases, cardiovascular diseases, disorders of the peripheral nervous system, disorders of the central nervous system, COPD, asthma, genito-urological disorders, or inflammation diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological diseases, cardiovascular diseases, disorders of the peripheral nervous system, disorders of the central nervous system, COPD, asthma, genito-urological disorders, or inflammation diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of GPR72 as well as pharmaceutical compositions comprising such compounds.

86. 发明申请

WO2003046179A2 NEW G-PROTEIN COUPLED RECEPTOR LUSTR2 AND USES THEREOF 审中-公开
标题翻译：新型G蛋白偶联受体LUSTR2及其用途
公开(公告)号：WO2003046179A2
公开(公告)日：2003-06-05
申请号：PCT/EP2002/012820
申请日：2002-11-15
申请人： BAYER AKTIENGESELLSCHAFT , GOLZ, Stefan , BRÜGGEMEIER, Ulf , GEERTS, Andreas
发明人： GOLZ, Stefan , BRÜGGEMEIER, Ulf , GEERTS, Andreas
IPC分类号： C12N15/12
CPC分类号： C07K14/705
摘要： Polynucleotide sequence for novel G-protein coupled receptor LUSTR2 and uses thereof. The present invention is directed to a polynucleotide sequence of a novel G-Protein Coupled Receptor LUSTR2. More particularly, the present invention provides a polynucleotide sequence comprising the nucleic acid sequence SEQ ID NO: 1 or nucleic acid sequences that hybridize to SEQ ID NO: 1 or its complimentary strand having at least 40% sequence identity. Preferably, the hybridizing nucleic acid sequence should hybridize under stringent conditions and in particular have 85% sequence identity, more preferably 90% sequence identity, and most preferably 95% sequence identity. The invention also provides the human LUSTR2 associated with the haemaotological, peripheral and central nervous system, COPD, asthma, genito-urological, metabolic diseases and pancreas and heart disorders as a result of relative quantification of the mRNA distribution in different human tissues by expression profiling. The invention also provides assays for the identification of compounds useful for the modulation of hematological, peripheral and central nervous system, COPD, asthma, genito-urological, metabolic diseases and pancreas and heart disorders for treating or preventing hematological, peripheral and central nervous system, COPD, asthma, genito-urological, metabolic diseases and pancreas and heart disorders associated with expression of the LUSTR2. The methods of the invention involve cell-free and cell-based assays that identify compounds which bind to and/or activate or inhibit the activity of LUSTR2, a G protein coupled receptor, followed by an in vivo assay of the effect of the compound on hematological, peripheral and central nervous system, COPD, asthma, genito-urological, metabolic diseases and pancreas and heart disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of LUSTR2 as well as pharmaceutical compositions comprising such compounds.
摘要翻译：新型G蛋白偶联受体LUSTR2的多核苷酸序列及其用途。本发明涉及新型G-蛋白偶联受体LUSTR2的多核苷酸序列。更具体地，本发明提供了包含核酸序列SEQ ID NO：1或与SEQ ID NO：1杂交的核酸序列或其具有至少40％序列同一性的互补链的多核苷酸序列。优选地，杂交核酸序列应在严格条件下杂交，特别是具有85％序列同一性，更优选90％序列同一性，最优选95％序列同一性。本发明还提供了与通过表达谱分析在不同人体组织中mRNA分布的相对定量相结合的血液学，外周和中枢神经系统COPD，哮喘，生殖泌尿，代谢疾病和胰腺和心脏病的人LUSTR2 。本发明还提供了用于鉴定可用于调节血液系统，外周和中枢神经系统，COPD，哮喘，泌尿系统，代谢疾病和胰腺以及用于治疗或预防血液学，外周和中枢神经系统的心脏病的化合物的测定， COPD，哮喘，生殖泌尿，代谢疾病，与LUSTR2表达相关的胰腺和心脏病。本发明的方法包括无细胞和基于细胞的测定，其鉴定结合和/或激活或抑制LUSTR2，G蛋白偶联受体的活性的化合物，随后在体内测定化合物对血液学，外周和中枢神经系统，COPD，哮喘，泌尿系统，代谢疾病和胰腺和心脏病。本发明还涉及结合和/或活化或抑制LUSTR2的活性的化合物以及包含这些化合物的药物组合物。

87. 发明申请

WO2010105770A1 SUBSTITUIERTE 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONE UND DEREN VERWENDUNG 审中-公开
标题翻译：取代的2-乙酰氨基-5-芳基-1,2,4-三唑酮及其用途
公开(公告)号：WO2010105770A1
公开(公告)日：2010-09-23
申请号：PCT/EP2010/001565
申请日：2010-03-12
申请人： BAYER SCHERING PHARMA AKTIENGESELLSCHAFT , BRÜGGEMEIER, Ulf , FÜRSTNER, Chantal , GEISS, Volker , KELDENICH, Jörg , KERN, Armin , DELBECK, Martina , KOLKHOF, Peter , KRETSCHMER, Axel , POOK, Elisabeth , SCHMECK, Carsten , TRÜBEL, Hubert
发明人： BRÜGGEMEIER, Ulf , FÜRSTNER, Chantal , GEISS, Volker , KELDENICH, Jörg , KERN, Armin , DELBECK, Martina , KOLKHOF, Peter , KRETSCHMER, Axel , POOK, Elisabeth , SCHMECK, Carsten , TRÜBEL, Hubert
IPC分类号： C07D233/70 , C07D249/12 , C07D409/04 , C07D413/12 , A61K31/4166 , A61K31/4196 , A61K31/422 , A61P9/00
CPC分类号： C07D233/70 , A61K9/0095 , A61K9/2054 , A61K31/4166 , A61K31/4196 , A61K31/422 , A61K45/06 , C07D249/12 , C07D409/04 , C07D413/12 , A61K2300/00
摘要： Die vorliegende Anmeldung betrifft neue, substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone, Verfahren zu ihrer Herstellung, ihre Verwendung allein oder in Kombinationen zur Behandlung und/oder Prävention von Krankheiten sowie ihre Verwendung zur Herstellung von Arzneimitteln zur Behandlung und/oder Prävention von Krankheiten, insbesondere zur Behandlung und/oder Prävention von kardiovaskulären Erkrankungen.
摘要翻译：本申请涉及新的取代的2-乙酰氨基-5-芳基-1,2,4-三唑酮，单独或用于疾病的治疗和/或预防和它们用于制备药物的对使用组合它们的制备方法，它们的用途治疗和/或预防疾病，特别是用于治疗心血管疾病的治疗和/或预防。

88. 发明申请

WO2010105750A1 TRIAZOL-DERIVATE ALS VASOPRESSIN-REZEPTOR INHIBITOREN ZUR BEHANDLUNG VON HERZINSUFIZIENZ 审中-公开
标题翻译：三唑衍生物作为加压素受体抑制剂来治疗心脏衰竭
公开(公告)号：WO2010105750A1
公开(公告)日：2010-09-23
申请号：PCT/EP2010/001442
申请日：2010-03-09
申请人： BAYER SCHERING PHARMA AKTIENGESELLSCHAFT , BRÜGGEMEIER, Ulf , FÜRSTNER, Chantal , GEISS, Volker , KELDENICH, Joerg , KERN, Armin , DELBECK, Martina , KOLKHOF, Peter , KRETSCHMER, Axel , POOK, Elisabeth , SCHMECK, Carsten , TRÜBEL, Hubert
发明人： BRÜGGEMEIER, Ulf , FÜRSTNER, Chantal , GEISS, Volker , KELDENICH, Joerg , KERN, Armin , DELBECK, Martina , KOLKHOF, Peter , KRETSCHMER, Axel , POOK, Elisabeth , SCHMECK, Carsten , TRÜBEL, Hubert
IPC分类号： C07D249/12 , A61K31/4196 , A61P9/04 , A61P1/16
CPC分类号： C07D249/12
摘要： Die vorliegende Anmeldung betrifft neue, substituierte Phenylalaninderivate, Verfahren zu ihrer Herstellung, ihre Verwendung allein oder in Kombinationen zur Behandlung und/oder Prävention von Krankheiten sowie ihre Verwendung zur Herstellung von Arzneimitteln zur Behandlung und/oder Prävention von Krankheiten, insbesondere zur Behandlung und/oder Prävention von kardiovaskulären Erkrankungen.
摘要翻译：本申请涉及新的取代的苯丙氨酸衍生物，它们的制备方法，单独或用于疾病的治疗和/或预防和它们用于制备药物用于治疗和/或预防的疾病中的用途的组合及其用途，特别是用于治疗和/或预防心血管疾病。

89. 发明申请

WO2008104295A2 UCP3 AS A BIOMARKER FOR PPARA MODULATORS 审中-公开
标题翻译： UCP3作为PPARA调节剂的生物标志物
公开(公告)号：WO2008104295A2
公开(公告)日：2008-09-04
申请号：PCT/EP2008/001201
申请日：2008-02-16
申请人： BAYER HEALTHCARE AG , GOLZ, Stefan , SUMMER, Holger , GEERTS, Andreas , WILMEN, Andreas , GRUSDAT, Gerda , BRÜGGEMEIER, Ulf
发明人： GOLZ, Stefan , SUMMER, Holger , GEERTS, Andreas , WILMEN, Andreas , GRUSDAT, Gerda , BRÜGGEMEIER, Ulf
IPC分类号： C12Q1/32 , C12Q1/68
CPC分类号： C12Q1/32 , G01N33/6893 , G01N2333/70567 , G01N2500/00 , G01N2800/00
摘要： The invention provides UCP3 as a biomarker for PPARa modulators. The invention relates to the identification of a biomarker or a set of biomarkers or a combination of molecular and clinical markers to monitor or identify or quantify a treatment with a PPARa modulator or a combination of one or more PPARa modulators with other pharmacological compounds.
摘要翻译：本发明提供了UCP3作为PPARα调节剂的生物标志物。本发明涉及鉴定生物标志物或一组生物标志物或分子和临床标志物的组合以监测或鉴定或定量用PPARα调节剂或一种或多种PPARα调节剂与其他药理学化合物的组合的治疗。 p>

90. 发明申请

WO2008104291A1 CPT1A AS A BIOMARKER FOR PPARA MODULATORS 审中-公开
标题翻译： CPT1A作为PPARA调制器的生物标记
公开(公告)号：WO2008104291A1
公开(公告)日：2008-09-04
申请号：PCT/EP2008/001197
申请日：2008-02-16
申请人： BAYER HEALTHCARE AG , GOLZ, Stefan , SUMMER, Holger , GEERTS, Andreas , WILMEN, Andreas , GRUSDAT, Gerda , BRÜGGEMEIER, Ulf
发明人： GOLZ, Stefan , SUMMER, Holger , GEERTS, Andreas , WILMEN, Andreas , GRUSDAT, Gerda , BRÜGGEMEIER, Ulf
IPC分类号： C12Q1/32 , C12Q1/68
CPC分类号： G01N33/6875 , C12Q1/48 , G01N2333/70567
摘要： The invention provides CPT1A as a biomarker for PPARa modulators. The invention relates to the identification of a biomarker or a set of biomarkers or a combination of molecular and clinical markers to monitor or identify or quantify a treatment with a PPARa modulator or a combination of one or more PPARa modulators with other pharmacological compounds.
摘要翻译：本发明提供CPT1A作为PPARa调节剂的生物标志物。本发明涉及鉴定生物标志物或一组生物标志物或分子和临床标志物的组合，以监测或鉴定或定量用PPARa调节剂或一种或多种PPARα调节剂与其它药理化合物的组合的治疗。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式